Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Udaya Kompella to Bevacizumab

This is a "connection" page, showing publications Udaya Kompella has written about Bevacizumab.

 
Connection Strength
 
 
 
0.373
 
  1. Tran J, Craven C, Wabner K, Schmit J, Matter B, Kompella U, Grossniklaus HE, Olsen TW. A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs. Invest Ophthalmol Vis Sci. 2017 07 01; 58(9):3732-3740.
    View in: PubMed
    Score: 0.138
  2. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013 Dec 02; 10(12):4676-86.
    View in: PubMed
    Score: 0.107
  3. Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 2013 Aug 05; 10(8):2858-67.
    View in: PubMed
    Score: 0.105
  4. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun; 27(3):219-24.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)